Jan Hoeijmakers presents new research results on the biology of aging at the world’s largest conference on aging research for drug discovery
Friday June 11th 2021, London – Jan Hoeijmakers, Ph.D., will share the latest research on DNA damage-induced transcription stress and its relationship to aging and neurodegeneration and the effects of diet on the world’s largest annual aging. present research and drug discovery conference (8th ARDD). Dr. Jan Hoeijmakers is Professor of Molecular Genetics at the Medical Center of the Erasmus University Rotterdam, The Netherlands.
Jan Hoeijmakers’ research focuses on the mechanism and clinical implications of mammalian DNA repair. His team cloned around half of all key genes involved in nucleotide excision and transcription-linked repair pathways, thus enabling the underlying molecular mechanisms to be elucidated. His laboratory generated the largest set of mouse repair mutants that provide insight into the etiology of human repair disorders such as Cockayne Syndrome (CS) and Trichothiodystrophy (TTD), including the identification of accelerated but true aging. He discovered that the accumulation of DNA damage and the resulting transcriptional stress are a major cause of systemic aging, but also trigger an anti-aging, calorie restriction (CR) -like “survival” response that increases resilience and maintenance mechanisms prioritized at the expense of growth.
His team found that applying CR to progeroid mouse repair mutants tripled lifespan and dramatically delayed all aspects of accelerated aging by reducing DNA damage, and at least partially revealed why CR delays aging. The counterintuitive clinical use of reduced diet in CS / TTD children greatly improved neurofunction and general health, and resulted in a complete abolition of the dietary guidelines for CS and TTD rather than more patients being given less food. These discoveries have far-reaching medical implications for many age-related diseases, most notably neurodegeneration, reducing the side effects of chemotherapy and radiation therapy, and ischemia-reperfusion damage associated with surgery and organ transplants.
“Understanding the molecular basis of aging will enable healthy aging,” said Dr. Jan Hoeijmakers, Professor of Molecular Genetics at Erasmus University Medical Center, Rotterdam, The Netherlands.
Jan Hoeijmakers leads research teams at the Princess Máxima Center for Pediatric Oncology (Utrecht), the CECAD in Cologne and the Erasmus Medical Center. He has received numerous (inter) national prizes and awards for his scientific achievements.
The conference proceedings of the ARDD are often published in peer-reviewed journals, whereby the lectures can be found at http: // www.
“Aging is developing into a drug disease in which several drugs are able to change the rate of aging in model organisms. ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find effective interventions and molecules to fight aging. The 2021 conference is the best so far with top-class speakers from all over the world. I’m really looking forward to meeting you in person at the University of Copenhagen in late summer, ”said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“Aging research is growing faster than ever in both science and industry. The ARDD meeting brings together experts from different fields and backgrounds and shares their latest groundbreaking research and developments with us. Our last ARDD meeting took place online and was a complete success. This year’s event will be a hybrid meeting with virtual and personal participants. I am particularly pleased that attending the ARDD Meeting 2021 gives young scientists a great opportunity to present their own work and meet experts in the field, ”said Daniela Bakula, Ph.D., University of Copenhagen
“Aging research is gaining in importance in the biopharmaceutical industry. To my knowledge, 6 of the top 30 pharmaceutical companies in the world have prioritized aging research for early discovery or therapeutic pipeline development, and several companies are using artificial intelligence to do this. We have been organizing ARDD’s annual conference and interest in aging biomarkers for eight years in a row and have seen registrations grow exponentially over the past two years, “said Alex Zhavoronkov, Ph.D., Co-Founder and CEO of Insilico Medicine, and the founder of Deep Longevity.
Building on the success of the ARDD conferences, the organizers developed the “Longevity Medicine” course series with some of the courses offered free of charge at Longevity.Degree in the recently published Lanced Healthy Longevity Paper entitled Longevity Medicine: Upskilling the Doctors of Tomorrow be treated.
Via Aging Research for Drug Discovery Conference
On the ARDD, leading personalities from the fields of aging, longevity and drug discovery will describe the latest advances in the molecular, cellular and organismic foundations of aging and the search for interventions. In addition, AI opinion leaders will attend the meeting to discuss the latest advances in this technology in the biopharmaceutical sector and how these can be applied to interventions. In particular, we are expanding this year with a workshop specifically for doctors, in which the latest knowledge about clinical interventions for healthy longevity will be described. ARRD aims to bridge clinical, academic and commercial research and promote collaborations that lead to practical solutions to one of mankind’s most difficult problems: aging. Our search? To extend the healthy lifespan of all people on the planet.
About Scheibye-Knudsen Lab
In the Scheibye-Knudsen laboratory we use in-silico, in-vitro and in-vivo models to understand the cellular and organismic consequences of DNA damage and to develop interventions. We discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules can alter the aging rate of model organisms. These results suggest that normal aging and age-related diseases can be malleable through similar interventions. The hope is to develop interventions that enable everyone to live healthier, happier, and more productive lives.
About deep longevity
Deep Longevity was acquired by Regent Pacific (SEHK: 0575.HK), whose shares are listed on the Hong Kong Stock Exchange. Deep Longevity develops explainable artificial intelligence systems to track the rate of aging on a molecular, cellular, tissue, organ, system, physiological and psychological level. It is also developing systems for the emerging field of longevity medicine that enable clinicians to make better decisions about interventions that can slow or reverse the aging process. Deep Longevity developed the Longevity as a Service (LaaS) © solution to integrate several deep biomarkers of aging, known as “deep aging clocks”, to provide a universal multifactorial measure of human biological age . Originally incubated by Insilico Medicine, Deep Longevity began its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other veteran AI and biotechnology investors supported the company. Deep Longevity has formed a research partnership with one of the world’s premier longevity organizations, Human Longevity, Inc. to bring a range of aging clocks to the network of advanced doctors and researchers. https: /
About Regent Pacific (SEHK: 0575.HK)
Regent Pacific is a diversified Hong Kong-based investment group that currently has a variety of corporate and strategic holdings focused on the healthcare, wellness and life sciences sectors. The group has a strong track record of investing and has returned approximately $ 298 million to shareholders in the 21 years of financial reporting since going public. https: /